Kornimate/medical-research-clean huggingface dataset:
virtual reality and 3d reconstruction in body image and bariatrics

Conditions: Obesity; Body Image Disorder; Bariatric Surgery Candidate

Summary: with obesity on the rise, the number of metabolic procedures performed annually is also increasing. bariatric surgery has a significant impact on metabolic disease but also results in significant weight loss. approximately, 30-40% of excess weight is lost within the first year following surgery. one of the motivating factors for surgery for patients is body image dissatisfaction and the stigmatisation of living with obesity, which is linked to low esteem, anxiety and depression. however, studies have indicated that following bariatric surgery, patients continue to experience dissatisfaction with their new body and identity due to unmet expectations. the investigators aim is to start addressing body image issues prior to surgery and provide realistic expectations to patients. this study will be focusing on the feasibility and acceptability of 3d image reconstruction and virtual reality as a method of helping bariatric patients manage their expectations and improve body image satisfaction after surgery. thereby, leading to better quality of life, improved psychological outcomes and prevention of disordered eating, anxiety and depression. the study will take place at st mary's hospital (london) and the west london nhs trust bariatric clinic from march 2022 to september 2022 (7 months). the study aims to recruit 10 participants from the tier 3 bariatric preoperative group. once the participant has provided written consent, a photograph of them will be taken using a handheld 3d scanner on a secure password protected device. the images will be processed to produce two reconstructed images, one with 15% less body weight and the second with 25% less body weight. the participants will be divided into groups of 5 and shown their reconstructed images using individual virtual reality headsets. the participants will only have access to their own images. this will be followed up with group peer discussion meetings and questionnaires.


Eligibility criteria:
inclusion criteria: * in the tier 3 preoperative bariatric group * 18 to 75 years old * male and female exclusion criteria: * anyone who cannot provide informed consent. * anyone with significant mental health instability

Keywords: virtual reality 3d reconstruction bariatric surgery
indications and outcomes in kidney-ureteral pediatric lithiasis: experience of parma

Conditions: Pediatric ALL; Stone, Urinary

Summary: incidence of paediatric urolithiasis is increasing in europe and north america. nowadays the management of stone disease is a common practice in not endemic country. the surgical's treatment is based on similar techniques as for adults. in the last years due to miniaturization of endoscopic instruments endourology has become the best approach to treat urinary stones in children. the investigators have retrospectively reviewed experience from 01/01/2000 to 28/02/2019 in children ≤ 16 years old affected by urinary stones who underwent rigid and flexible ureterorenoscopy and pecutaneous nephrolitotripsy procedures and recorded clinical data, overall success rate and complication.


Eligibility criteria:
inclusion criteria: * 0-17 yrs old, urinary stones (kidney, ureteral, not bladder), with or without malformations or metabolic diseases exclusion criteria: * none
mass in motion kids in the clinical setting

Conditions: Overweight; Obesity

Summary: mass in motion kids is a whole-of-community intervention in fitchburg and new bedford, massachusetts that incorporates evidence-based interventions across multiple sectors and at multiple levels. the overall goal of the study is to examine the extent to which the comprehensive, systematic intervention reduces childhood obesity among underserved children. the clinical intervention implements evidence-based interventions each city's federally-qualified community health center. intervention components aim to improve primary and secondary prevention of childhood obesity and implement changes at four levels: clinician; parent-family; organizational; and environmental. we additionally provide training and educational materials to other pediatric clinicians in the two communities. the clinical intervention components include (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. healthy weight clinics (hwc); (4) integrating community health workers into the primary care and hwc teams; and (5) health center environmental changes to support behavior change modification.


Eligibility criteria:
inclusion criteria: * children aged 2-12 years * patient of the community's federally qualified health center
genomic study in non-small cell lung cancer brain metastasis

Conditions: NSCLC Stage IV; Brain Metastases

Summary: the investigators collected the data from the investigators' center between january 2011 and october 2020. the study included all non-small cell lung cancer patients with surgically excised brain metastasis. the investigators analysis the correlation of gene mutation and the disease course.

the investigators collected the data from from the investigators' center between january 2011 and october 2020. the study included all non-small cell lung cancer patients with surgically excised brain metastasis. the investigators analysis the correlation of gene mutation and the disease course. the investigators use kaplan-meier regression to analyze the overall survival, and the difference between the groups was calculated using log rank test. cox proportional hazards method was used to create the regression model and estimate the hazard ratios.

Eligibility criteria:
inclusion criteria: - patients diagnosed with non-small cell lung cancer who underwent craniectomy and subsequent whole brain radiotherapy and associated chemo or target therapy exclusion criteria: * patient who did not receive postoperative adjuvant therapy
lactobacillus reuteri dsm17938 in c-section infants

Conditions: C-section

Summary: rct designed to evaluate the impact of lactobacillus reuteri dsm17938 to modify gut microbiota in children delivered by c-section

rct designed to evaluate the safety and efficacy of l. reuteri dsm17938 administrated to newborns babies to modify the fecal microbiome after 30 days of supplementation. secondary secondary endpoints will be evaluate the occurrence and frequency of aes day 0 to day 60; the gut bacterial composition day 7 and day 30 as described in primary endpoint; the gut bacterial composition in infants born by c-section and supplemented with l. reuteri dsm17938 compared to the gut bacterial composition in infants born vaginally and the salivary concentration of iga at 48h ±3h after birth and at day 30.

Eligibility criteria:
inclusion criteria: * gestational age \>37weeks +0 days and \<39 weeks +0 days * birth weight appropriate for gestational age (aga) or large for gestational age (lga) * apgar score 8 or greater * children will receive more than 50% of the feeding occasions with human breastmilk * mothers will have the intention to exclusively or predominantly breastfeed the subject. on the diary report form mother will report day by day the frequency of human lactation and the frequency and amount of infant formula. * readiness and the opportunity for parents to fill out a study diary, questionnaires. * parent(s) are willing to postpone major changes in the infant feeding mode, and * written informed consent from parents exclusion criteria: * older than 24 hours after birth when given the first dose of investigational product * any kind of chronic or acute diseases during pregnancy that can modify fecal microbiota in children, e.g. gestational diabetes, pre-clampsia, gastrointestinal disease * congenital malformations or anomalies * maternal use of antibiotics from gestational week 33 and throughout the study period. * maternal use of probiotics from gestational week 33 and throughout the study period. * maternal severe obesity at inclusion or at delivery evaluated using rosso madrones centiles * infant use of antibiotics throughout the study period. * infant use of probiotics throughout the study period, including infant formula and/or supplementation. * infants carrying out general anesthesia * meconium aspiration syndrome * history of premature disruption of membranes for \>24h * participation in other clinical trials
the effect of home visit supported nursing education program on some parameters in elderly people living alone at home

Conditions: Old Age; Debility; Loneliness; Healthy Lifestyle

Summary: it is aimed to develop healthy lifestyle behaviors of elderly people living alone at home, reduce their loneliness levels and increase their social support capacity.the research was planned as a quasi-experimental research. the research population consists of elderly people living alone at home who are registered to the elderly and home care unit of a municipality of a province.

when elderly people want to live in their own homes, an important issue arises: loneliness. loneliness is a common problem among older adults and has become increasingly common in recent years. loneliness not only affects psychological well-being, but also negatively affects physical health, increasing the likelihood of illness and death.when people live longer, they are more likely to experience health problems such as physical weakness, cognitive decline, and chronic diseases. weakness among older people creates a state of vulnerability that increases the risk of adverse health outcomes, leading to reduced daily activities and the need for long-term care.this study aims to develop healthy lifestyle behaviors, reduce loneliness levels and increase social support capacity of elderly people living alone at home.the research was planned as a quasi-experimental research. the research population consists of elderly people living alone at home who are registered to the elderly and home care unit of a municipality of a province. elderly people who are registered to a home care unit, live alone, and are over the age of 65 and agree to work will be included in the research. individuals under the age of 65 and those with mental disabilities will be excluded from the study. the independent variable of the research is; the status of receiving a home visit supported nurse care program was determined as the dependent variable of the study: healthy lifestyle behaviors scale ii score, loneliness scale score, social support scale score.

Eligibility criteria:
inclusion criteria: * being 65 years or older * receiving home care services * agreeing to participate in the study * be literate exclusion criteria: * individuals under the age of 65 * be mentally retarded * not volunteering

Keywords: elderly home visit nursing
to evaluate drug-drug interactions between dwn12088 and pirfenidone or nintedanib in healthy volunteers

Conditions: Idiopathic Pulmonary Fibrosis

Summary: an open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between dwn12088 and pirfenidone or nintedanib in healthy volunteers

this clinical trial is an open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between dwn12088 and pirfenidone or nintedanib in healthy volunteers

Eligibility criteria:
inclusion criteria: * healthy adults aged ≥ 19 and ≤ 55 years at screening * subjects who voluntarily decided to participate in the study and provided written consent to after receiving a detailed explanation on this study and fully understanding the information exclusion criteria: * subjects who received another investigational agent in another study (including bioequivalence study) within 180 days prior to the first dose of the ip (the end of prior study participation will be the date of the last dose, and the days will be counted from the next day \[1 day\].) * female subjects who are pregnant or lactating
low molecular weight heparin for hemodialysis anticoagulation

Conditions: End Stage Renal Failure on Dialysis

Summary: low-molecular weight heparins (lmwhs) as well as unfractionated heparin (ufh) is used as anticoagulation during hemodialysis (hd) therapy. in this study the investigators have compared clinical efficacy and safety of lmwh and ufh, and their effect on lipid profile.

in this prospective, randomized, cross-over study the investigators compared the safety, clinical efficacy of clexane (enoxaparin sodium; sanofi-aventis) with unfractionated heparin in 27 chronic hd patients. group a received clexane (enoxaparin sodium; sanofi-aventis) and were followed up for 3 months and then crossed over to unfractionated heparin for a further 3-month period. group b received unfractionated heparin first and then crossed over to clexane, each followed up for 3 months. heparin anticoagulation, clinical clotting and hemorrhage were evaluated by visual inspection after blood draining of the air trap.

Eligibility criteria:
inclusion criteria: * patients in end stage renal failure requiring maintenance dialysis were recruited into the study exclusion criteria: * patients with known bleeding disorders * subjects receiving oral or other forms of anticoagulant therapy (e.g. warfarin, aspirin) or drugs that could affect heparin activity (e.g. digitalis, tetracyclines, and antihistamines) were also excluded. subjects continued their usual medication (including lipid-lowering therapy ) and were treated in the normal manner by their caring physicians during the study.

Keywords: anticoagulation hemodialysis heparin lipids low molecular weight heparins
intervention to prevent fall injuries to young children in the home

Conditions: Wounds and Injuries

Summary: currently, six public health units (phus) in southwestern ontario are taking part in the developed and implementation of a social marketing intervention campaign aimed at lowering the incidence of falls to children in the home; city of hamilton - public health services (control), durham public health, haldimand-norfolk health unit, niagara region public health, wellington-dufferin-guelph public health and windsor public health (control). this campaign is based on community-based intervention research and 'best practices' for improving parent attitudes and behaviours toward child safety. the campaign will focus on increasing parents' awareness and knowledge of fall injuries, positively impact parental attitudes to motivate them to want to implement strategies to reduce fall risks, and increase parental safety practices that would counteract the most common mechanisms that contribute to home falls for children at these young ages. the campaign will run from september 2013 through august 2014. the phus' social marketing campaign will strategically disseminate different materials to their respective communities: printed materials (posters, pamphlets), video modules about parenting safety, safety information through an e-health website, and direction communication with parents through family health team practitioners. the proposed research project will request archival data from canadian institute of health information (cihi), specifically from their national ambulatory care reporting system (nacrs), on frequency of falls in the home to determine the extent to which the social marketing campaign is effective. comparing pre-, during and post-intervention levels in the phu communities will determine if and which social marketing strategies were effective. additionally, random digit dialing will be used to assess pre vs post parental fall related attitudes, behaviors and intervention exposure. this evaluation will provide the first ever test of a community level intervention to reduce childhood falls in the home in canada and will provide valuable information about what constitutes 'best practices' for preventing falls in the home among children 1 through 4 years of age.


Eligibility criteria:
inclusion criteria: * must be a parent or primary care giver of a child 1 through 4 years of age * must live in one of the designated communities (by postal code) exclusion criteria: -
a study of ganetespib in subjects with alk-positive non-small-cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: phase 2 study of subjects with alk positive, advanced nsclc who have failed up to 3 prior therapies. the study will take place globally at multiple study centers. subjects will be enrolled to receive ganetespib one time per week for three weeks followed by a rest week; and will repeat this schedule until the cancer gets worse or the subject is unable to tolerate ganetespib. the primary goal of the study is to determine how ganetespib is tolerated and how active it is in alk positive nsclc.


Eligibility criteria:
inclusion criteria: * males or females aged 18 years or older * pathological confirmation of advanced nsclc * evidence of a translocation or an inversion event involving the alk gene locus * ecog performance status 0 or 1 exclusion criteria: * prior therapy with alk-targeted agents * prior treatment with hsp90 inhibitor * known egfr activating mutation * presence of active or untreated central nervous system (cns) metastases
renal tubular disorders in egyptian children

Conditions: Renal Tubular Disorders in Children

Summary: renal tubules play an important role in fluid, electrolyte, and acid-base homeostasis. defect of these functions can give rise to a host of disorders. these disorders can lead to life threatening disturbances in electrolytes and acid-base balance. in egypt, there is little data about these disorders. many of these cases are diagnosed late, therefore early suspicion for diagnosis can improve the overall clinical outcome of these children.

renal tubules play an important role in fluid, electrolyte, and acid-base homeostasis. defect of these functions can give rise to a host of disorders. these disorders can lead to life threatening disturbances in electrolytes and acid-base balance. in egypt, there is little data about these disorders. many of these cases are diagnosed late, therefore early suspicion for diagnosis can improve the overall clinical outcome of these children. as a result, starting management early will help those children have a better life. therefore awareness about these disorders and long-term outcome is really important. the investigators present the clinical characterizations of many tubular disorder and the follow up in our center. the aim of this study is to reveal the different clinical presentations and the main lab features of renal tubular disorders in children to promote early recognition and management.

Eligibility criteria:
inclusion criteria: * all children aged from one month to 18 years who have renal tubular disorders. exclusion criteria: * children who have renal tubular disorders secondary to drugs, intoxication, obstructive uropathy or transient in nature.

Keywords: renal tubular disorders failure to thrive metabolic acidosis metabolic alkalosis hypokalemia
transversus abdominis plane block vs continuous infiltration wound catheter for analgesia after caesarean section

Conditions: Postoperative Pain

Summary: analgesia following surgery associates different intra-venous or oral analgesic drugs and sometimes opioids. to reduce opioid consumption, loco-regional anaesthesia might be administered as a complement. in the specific context of caesarean sections, pain control is mandatory to enable the mother to take care of her offspring and shorten their hospital stay. this intervention is mainly performed under neuraxial anaesthesia (spinal or epidural), enabling the injection of morphine in the subdural or epidural space, as part of a multimodal analgesia regimen. studies have evaluated continuous wound infiltration catheters (cic) and ultrasound-guided (ugd) transabdominis plane (tap) block, and both techniques and both techniques reduce postoperative morphine consumption. recent studies have compared the two techniques and found conflicting results. furthermore, they did not consider caesarean section performed under epidural analgesia, with a different neuraxial injection site, neither did they compared pain after postoperative day 2. consequently, the aim of this study was to compare resting and standing pain up to postoperative day 3 after caesarean section performed under spinal or epidural anaesthesia and receiving either usg-tap block or cic. baseline hypothesis was that the continuous infiltration provided a better analgesia at day 2.


Eligibility criteria:
inclusion criteria: * informed consent, * age\>/=18 years, * caesarean section under spinal or epidural anaesthesia * technique surgical "cohen stark méthod". exclusion criteria: * patient refusal, * patient under guardianship, * contraindication to one of the two techniques, * cesarean section under general anesthesia * allergies to local anesthetics * maternal instability
real-world evaluation of brolucizumab for the treatment of neovascular (wet) age-related macular degeneration (amd) (iris study)

Conditions: Age-related Macular Degeneration (AMD)

Summary: this study was a retrospective cohort study of patients to assess the early insights into real-world safety among wet amd patients initiating brolucizumab. evidence was generated to describe their patient characteristics and clinical outcomes. the study was conducted using the iris registry.

iris registry ehr data from patients with wet amd who initiated brolucizumab were analyzed in this study. identification period of the index date (index period): the patients fulfilling the selection criteria was identified * index date: defined as the date of the earliest brolucizumab injection * study period: the period from the first patient eye exposure to brolucizumab to the last follow-up recorded * pre-index period: the period 36 months prior to the index date. data within 36 months prior to the index date will be used to assess baseline characteristics. * post-index period: the period 180 days after the index date

Eligibility criteria:
inclusion criteria: 1. ≥1 healthcare common procedure coding system (hcpcs) code (j code) or emr note for treatment with brolucizumab during the index period (date of earliest code or emr note = index date) 2. ≥18 years old on the index date 3. ≥1 current procedural terminology (cpt) code for intravitreal administration on the index date 4. ≥1 international classification of diseases, clinical modification-9/10 (icd-9/10) code for wet amd in the 36 months prior to or on the index date o note: off-label use of brolucizumab is not expected given payer access restrictions in the us. 5. ≥1 follow-up visit after the index date 6. ≥1 va assessment on the index date or within 90 days prior to the index date exclusion criteria: 1. use of brolucizumab prior to 10/8/2019 (e.g. clinical trials) 2. unknown laterality of the index eye on the index date

Keywords: brolucizumab, intravitreal injection, neovascular age-related macular degeneration, visual acuity